{"abstract": "A promising new class of cholesterol-lowering drugs known as PCSK9 inhibitors is being developed.", "web_url": "https://www.nytimes.com/2013/11/15/business/questions-for-a-new-class-of-cholesterol-drugs.html", "snippet": "A promising new class of cholesterol-lowering drugs known as PCSK9 inhibitors is being developed.", "lead_paragraph": "New guidelines governing the use of cholesterol-lowering medicines are a huge change for doctors and a vast number of patients, but the impact on the drug industry is expected to be less tumultuous.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/15/business/SubPharma/SubPharma-articleLarge.jpg", "height": 410, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2013/11/15/business/SubPharma/SubPharma-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 410}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/15/business/SubPharma/SubPharma-jumbo.jpg", "height": 700, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/15/business/SubPharma/SubPharma-superJumbo.jpg", "height": 1324, "width": 1938, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/15/business/SubPharma/SubPharma-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2013/11/15/business/SubPharma/SubPharma-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/15/business/SubPharma/SubPharma-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Questions for a New Class of Cholesterol Drugs", "kicker": null, "content_kicker": null, "print_headline": "Questions for a New Class of Cholesterol Drugs", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "persons", "value": "Thomas, Katie", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Statins (Cholesterol-Lowering Drugs)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Generic Brands and Products", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Regeneron Pharmaceuticals Inc", "rank": 6, "major": "N"}, {"name": "subject", "value": "Crestor (Drug)", "rank": 7, "major": "N"}, {"name": "subject", "value": "Vytorin (Drug)", "rank": 8, "major": "N"}, {"name": "subject", "value": "Zetia (Drug)", "rank": 9, "major": "N"}, {"name": "organizations", "value": "Merck & Company Inc", "rank": 10, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 11, "major": "N"}, {"name": "subject", "value": "Cholesterol", "rank": 12, "major": "N"}, {"name": "subject", "value": "Heart", "rank": 13, "major": "N"}], "pub_date": "2013-11-15T02:50:42+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Katie Thomas", "person": [{"firstname": "Katie", "middlename": null, "lastname": "Thomas", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/93a3433d-9389-5cb5-b440-c539fe1535a9", "word_count": 862, "uri": "nyt://article/93a3433d-9389-5cb5-b440-c539fe1535a9"}